#hatch-waxman

[ follow ]
#supreme-court #skinny-label #induced-infringement #certiorari #skinny-label-generics
Intellectual property law
fromPatently-O
3 days ago

Supreme Court Patent Update: Hikma Redistributed, Curtin's Missing Brief, and Two Petitions on Deck

Supreme Court denied cert in two matters but redistributed Hikma v. Amarin to January 16, increasing the likelihood of grant amid government support.
#skinny-label
fromPatently-O
2 weeks ago
Intellectual property law

Supreme Court's January 2026 IP Docket: Hikma Leads a Small but Significant Field

Hikma v. Amarin questions whether a skinny-label generic can face induced infringement for calling its product a 'generic version' or citing branded sales.
fromPatently-O
1 month ago
Intellectual property law

Label-Plus Liability: The Government Warns the Federal Circuit Misread Hatch-Waxman

The Solicitor General urges Supreme Court review to clarify that FDA-compliant skinny labels and basic commercial statements should not automatically constitute inducement of patent infringement.
fromPatently-O
2 weeks ago
Intellectual property law

Supreme Court's January 2026 IP Docket: Hikma Leads a Small but Significant Field

fromPatently-O
1 month ago
Intellectual property law

Label-Plus Liability: The Government Warns the Federal Circuit Misread Hatch-Waxman

more#skinny-label
fromPatently-O
2 months ago

Supreme Court on Patents Fall 2025

The leading contender is Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889, which asks whether a generic drug manufacturer that fully carves patented uses out of its FDA-approved label can nonetheless face induced infringement liability simply by calling its product a "generic version" of the brand-name drug or referencing publicly available information about the branded product's sales. The
Intellectual property law
[ Load more ]